Invuity, Inc. (IVTY) Raised to “Sell” at ValuEngine
ValuEngine upgraded shares of Invuity, Inc. (NASDAQ:IVTY) from a strong sell rating to a sell rating in a research note released on Friday morning.
IVTY has been the topic of several other reports. Zacks Investment Research raised Invuity from a sell rating to a hold rating in a report on Thursday, May 25th. Northland Securities set a $13.00 target price on Invuity and gave the stock a buy rating in a report on Tuesday, June 13th. William Blair reissued a buy rating on shares of Invuity in a report on Tuesday, May 23rd. Finally, Piper Jaffray Companies reissued a buy rating and issued a $10.00 target price on shares of Invuity in a report on Wednesday, July 26th. Two analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. The company presently has an average rating of Hold and an average price target of $13.20.
Shares of Invuity (NASDAQ:IVTY) traded up 3.75% during mid-day trading on Friday, hitting $8.30. The company had a trading volume of 229,254 shares. Invuity has a 12-month low of $4.50 and a 12-month high of $14.25. The firm’s 50 day moving average is $7.17 and its 200-day moving average is $7.65. The firm’s market cap is $141.52 million.
Invuity (NASDAQ:IVTY) last released its quarterly earnings data on Tuesday, July 25th. The medical instruments supplier reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by $0.07. The company had revenue of $9.77 million for the quarter, compared to analyst estimates of $10.30 million. Invuity had a negative net margin of 114.61% and a negative return on equity of 140.69%. On average, equities analysts expect that Invuity will post ($2.38) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Invuity, Inc. (IVTY) Raised to “Sell” at ValuEngine” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/09/04/invuity-inc-ivty-raised-to-sell-at-valuengine.html.
Several institutional investors and hedge funds have recently made changes to their positions in IVTY. Bank of Montreal Can acquired a new position in shares of Invuity in the 1st quarter worth approximately $112,000. Cowen Prime Services LLC boosted its holdings in shares of Invuity by 10.7% in the 1st quarter. Cowen Prime Services LLC now owns 342,250 shares of the medical instruments supplier’s stock worth $2,721,000 after acquiring an additional 33,000 shares in the last quarter. FMR LLC boosted its holdings in shares of Invuity by 0.5% in the 1st quarter. FMR LLC now owns 829,564 shares of the medical instruments supplier’s stock worth $6,595,000 after acquiring an additional 4,264 shares in the last quarter. Dialectic Capital Management LP boosted its holdings in shares of Invuity by 67.7% in the 1st quarter. Dialectic Capital Management LP now owns 394,000 shares of the medical instruments supplier’s stock worth $3,132,000 after acquiring an additional 159,000 shares in the last quarter. Finally, Royce & Associates LP boosted its holdings in shares of Invuity by 84.4% in the 1st quarter. Royce & Associates LP now owns 40,906 shares of the medical instruments supplier’s stock worth $325,000 after acquiring an additional 18,726 shares in the last quarter. 71.18% of the stock is currently owned by institutional investors and hedge funds.
Invuity Company Profile
Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Stock Ratings for Invuity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity Inc. and related stocks with our FREE daily email newsletter.